Slon Dry
Slon Dry Antiseptic*
2 QUALITATIVE AND QUANTITATIVE COMPOSITIONPovidone Iodine 1.14% w/w
For excipients see 6.1
3 PHARMACEUTICAL FORMCutaneous Spray, Powder
* Alternative name also applies throughout text
4 CLINICAL PARTICULARS4.1 Therapeutic indicationsSlon Dry is a broad spectrum antiseptic for topical application in the treatment and prevention of infection in wounds. May be used in first aid for minor cuts, grazes, burns, abrasions and blisters.
4.2 Posology and method of administrationShake the can before use and spray the treatment area from a distance of 6-9 inches (15-22 cm) until a light dusting of powder is deposited. Slon Dry should be used directly from the aerosol container.
Adults:
The recommended usual maximum daily adult application for regular use on broken skin is 150 mg ailable iodine.
Children and elderly patients:
There are no special dosage recommendations for either elderly patients or children. However, povidone-iodine is not recommended for regular use in neonates and is contra-indicated in very low birth weight infants (below 1500 g)-
4.3 ContraindicationsSlon Dry is contraindicated in patients with:
• Hypersensitivity to povidone-iodine or to any of the excipients
• Thyroid disorders, in particular overactive thyroid (hyperthyroidism), nodular colloid goitre, endemic goitre and Hashimoto’s thyroiditis.
• Scheduled radioiodine therapy
4.4 Special warnings and precautions for use• Avoid application of povidone-iodine into the eyes and nose. Care must be taken when Slon Dry is used on known iodine sensitive subjects, although these do not normally react to povidone-iodine.
• Povidone-iodine can be absorbed systemically during the topical treatment of burns and large areas of broken skin. The degree of absorption is proportional to the depth and extent of the burn or broken skin.
• Prolonged treatment with povidone-iodine of patients with severe and extensive burns may cause metabolic acidosis, hypernatraemia and renal impairment. In patients at risk Slon Dry should be used with caution.
• Special caution is needed in patients with pre-existing renal insufficiency and in neonates and infants up to 6 months of age, pregnant and breastfeeding women. In such cases benefit/risk assessment should be performed and monitoring of thyroid function should be considered.
4.5 Interaction with other medicinal products and other forms of interactionAbsorption of iodine from povidone-iodine may interfere with thyroid function tests by causing an increase in protein bound iodine levels. Contamination with povidone-iodine of several types of tests for the detection of occult blood in urine may produce false positive results.
Do not mix or co-administer with disinfectants and/or antiseptics or other agents used for the treatment of wounds.
There is a risk of (transient) hypothyroidism after regular or prolonged use in patients on concomitant lithium therapy.
4.6 Fertility, Pregnancy and lactationPregnancy and breastfeeding
Limited data is ailable on the use of this product in pregnant women. Excessive use of povidone-iodine should be oided in pregnant or lactating women because absorbed iodine can cross the placental barrier and is secreted in breast milk.
Under these circumstances, povidone-iodine should only be administered if clearly necessary.
Fertility
No data is ailable on fertility outcomes.
4.7. Effects on ability to drive and use machinesPovidone-iodine has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effectsAdverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (> 1/10) common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to < 1/1,000); very rare (< 1/10,000) or unknown (can not to be estimated from ailable data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Immune system disorders
Rare: Hypersensitivity
Very rare: Anaphylactic reaction
Endocrine disorders
Very rare: Hyperthyroidism
Metabolism and nutrition disorders
Unknown: Metabolic acidosis, hypernatraemia
Skin and subcutaneous tissue disorders
Rare: Skin reaction localised
Renal and urinary disorders
Unknown: Renal impairment
Povidone-iodine may produce local skin reactions although it is considered to be less irritant than iodine.
The application of povidone-iodine to large wounds or severe bums may produce systemic adverse effects such as metabolic acidosis, hypernatraemia and impairment of renal function.
4.9 OverdoseWith normal topical application, iodine absorption is so low that the risk of overdose can be virtually excluded.
The amount of povidone-iodine contained in one aerosol can of Slon Dry is unlikely to he any toxic effects if ingested.
Iodine ingested in large amounts can produce goitre and hypothyroidism as well as hyperthyroidism and may lead to a range of adverse effects, often called iodism, such as metallic taste, vomiting, abdominal pain or bloody diarrhoea, although some of the effects may be due to hypersensitivity.
Treatment of iodine poisoning consists of gastric lage with a starch solution (15 g starch or flour in 500 ml water); in severe cases, with sodium thiosulphate 1 - 5% as a specific antidote. Gastric irritation can be reduced with milk. Monitoring of the fluid and electrolyte balance should be useful.
High serum iodine levels resulting from excessive use can be reduced by haemodialysis.
5 PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic propertiesPharmacotherapeutic group: antiseptic and disinfectant ATC code: D08AG02
Povidone-iodine is an antiseptic which liberates iodine in contact with the skin.
Povidone iodine is a broad spectrum anti-microbial agent with activity against a wide variety of bacteria, including acid fast bacilli and bacterial spores. It is also active against fungi, a wide range of viruses and protozoa.
5.2 Pharmacokinetic propertiesPovidone-iodine administered clinically via any route can result in systemic absorption of iodine. The amount of absorbed iodine will vary according to the concentration of the povidone-iodine preparation used, the number of applications and the route of administration. Whilst absorption of iodine may occur following topical administration of all povidone-iodine preparations, the effects are dose related. In view of the fact that a 10 second burst will deliver only 7mg of ailable iodine, the levels of iodine likely to be absorbed following administration of Slon Dry will be exceedingly small and the effects on the internal organs minimal.
Any increase in the blood iodine level is generally transient. In patients with a healthy thyroid, the increased iodine level does not lead to any clinically relevant changes in thyroid hormone status. When iodine metabolism is normal, increased amounts of iodine are excreted via the kidneys.
5.3 Preclinical safety dataThere are no findings in the preclinical testing which are of relevance to the prescriber.
6 PHARMACEUTICAL PARTICULARS6.1 List of excipientsPovidone N-Pentane Soya lecithin Butane 40
6.2 IncompatibilitiesAlkali will reduce the anti-microbial activity of povidone-iodine.
6.3 Shelf life3 years.
6.4 Special precautions for storagePRESSURISED CONTAINER: Protect from sunlight.
DO NOT - expose to temperatures exceeding 50°C.
- pierce or burn, even after use.
- spray on a naked flame or any incandescent material.
- apply while you are smoking. Keep away from sources of ignition.
Do not store above 25°C.
6.5. Nature and contents of containerMonobloc aluminium aerosol container, internally lacquered, containing micronised powder and propellants under pressure and fitted with a valve and actuator and transparent yellow polypropylene overcap.
The aerosol containers may be provided as items in first aid kit containers.
6.6 Special precautions for disposalMedicines should be kept out of the reach of children.
7. MARKETING AUTHORISATION HOLDER
Novartis Consumer Health UK Ltd Park View, Riverside Way Watchmoor Park, Camberley Surrey GU15 3YL
Trading style: Novartis Consumer Health
8 MARKETING AUTHORISATION NUMBER(S)PL 00030/0124
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION15 April 1998
10 DATE OF REVISION OF THE TEXT26/11/2014